Article Dans Une Revue The Lancet Gastroenterology & Hepatology Année : 2024

Global differences in the management of alcohol-associated hepatitis.

H. Blaney
  • Fonction : Auteur
L. A. Díaz
  • Fonction : Auteur
N. Li
  • Fonction : Auteur
G. Malhi
  • Fonction : Auteur
R. Mortuza
  • Fonction : Auteur
X. Qi
  • Fonction : Auteur
A. V. Kulkarni
  • Fonction : Auteur
R. Bataller
  • Fonction : Auteur
J. Cabezas
  • Fonction : Auteur
E. B. Tapper
  • Fonction : Auteur

Résumé

Alcohol-associated hepatitis is characterised by jaundice and malaise in individuals with excessive and chronic alcohol intake, and is associated with high short-term mortality.1 Specific treatments for alcohol-associated hepatitis are scarce, and treatment for the underlying alcohol use disorder (AUD) is often neglected in clinical practice.2 Management of severe alcohol-associated hepatitis is mainly based on supportive therapy, including nutrition and treating infections as they arise. Corticosteroids have been used to treat alcohol-associated hepatitis since the 1970s and remain the only effective treatment, although multiple studies show inadequate efficacy.1 Early liver transplantation has emerged as a novel strategy to improve survival in severe alcohol-associated hepatitis,3 yet access is not universally available.4 Little is known about international practice variations in managing alcohol-associated hepatitis. We aimed to examine practice patterns regarding the treatment of alcohol-associated hepatitis and adherence to current clinical guidelines and evidence.
Fichier non déposé

Dates et versions

hal-04887701 , version 1 (15-01-2025)

Identifiants

Citer

H. Blaney, L. A. Díaz, N. Li, G. Malhi, R. Mortuza, et al.. Global differences in the management of alcohol-associated hepatitis.. The Lancet Gastroenterology & Hepatology, 2024, The Lancet Gastroenterology & Hepatology, 9 (11), pp.972-974. ⟨10.1016/S2468-1253(24)00232-2⟩. ⟨hal-04887701⟩

Collections

RIIP UNIV-LILLE
0 Consultations
0 Téléchargements

Altmetric

Partager

More